LID26 Oct 2011 15:18
Commenting on the results Terry O'Brien, Chief Executive, said: "The Board is pleased with the progress that has been made during the period, with revenues significantly increasing and the Company securing high quality partners in key territories such as Japan. Notably, we have reduced the operating loss by 58%, making considerable progress towards profitability. The Company's product offering has been broadened, our intellectual property position strengthened, and our global market reach continues to grow. As the market for minimally invasive hemodynamic monitoring increases, particularly driven by the focus on improving efficiency in global healthcare systems, LiDCO is well placed to capitalize on this growth.
"Going into the second half of 2011, the Board believes that the Company is in a strong position for growth both in the UK and internationally through working closely with our strategically important distribution partners. We anticipate a profitable second half to the year and look forward to reporting further progress as our business and the hemodynamic monitoring market continues to grow."